SCHEMBL5020874

SCHEMBL5020874

CS(=O)(=O)c1cccc(Cl)c1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PGR P06401 6/20 0.52
MEN1 O00255 1/20 0.52
ALDH1A1 P00352 1/20 0.52
KMT2A Q03164 1/20 0.52
ADORA3 P0DMS8 1/20 0.50
ADORA2A P29274 1/20 0.50
ADORA2B P29275 1/20 0.50
ADORA1 P30542 1/20 0.50
MMP2 P08253 1/20 0.50
PKM P14618 1/20 0.49
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
AKR1C3 P42330 2/20 0.46
AKR1C2 P52895 1/20 0.46
AKR1C1 Q04828 1/20 0.46
PTGS2 P35354 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31281283 1.00 PGR (0.52) PGRMEN1ALDH1A1KMT2AADORA3
Bicarbonate SCHEMBL12613772 0.92 ADORA3 (0.53) PGRMEN1ALDH1A1KMT2AADORA3
SCHEMBL10051059 0.83 CA1 (0.55) ALDH1A1
SCHEMBL23208318 0.81 PGR (0.46) PGRMEN1ALDH1A1KMT2AMMP2
SCHEMBL31435391 0.81 AKR1B1 (0.56) PGRMEN1ALDH1A1KMT2AMMP2
SCHEMBL2199161 0.81 AKR1B1 (0.56) PGRMEN1ALDH1A1KMT2AMMP2
SCHEMBL294450 0.79 PGR (0.53) PGRMEN1ALDH1A1KMT2AMMP2
SCHEMBL8477676 0.79 ALDH1A1 (0.59) PGRMEN1ALDH1A1KMT2AMMP2
SCHEMBL29422524 0.79 ALDH1A1 (0.54) PGRMEN1ALDH1A1KMT2AMMP2
SCHEMBL294451 0.79 ALDH1A1 (0.59) PGRMEN1ALDH1A1KMT2AMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106866507-A A kind of synthetic method for tieing up not Buddhist nun 武汉博诚恒瑞医药科技有限公司 2017-06-20 CN claimed
EP-3632892-B1 METHOD FOR PRODUCING 3-ARYLPROPIONAMIDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2024-07-31 EP disclosed
US-20240092780-A1 ADDUCTS AND DIMER COMPOUNDS SYNTHESIZED USING GK METHOD ANKH LIFE SCIENCES LIMITED (IE) 2024-03-21 US disclosed
WO-2023214412-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE PRILENIA NEUROTHERAPEUTICS LTD. (IL) 2023-11-09 WO disclosed
US-20230339878-A1 SLC26A3 INHIBITORS AND USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-26 US disclosed
US-20230339878-A1 SLC26A3 INHIBITORS AND USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-26 US disclosed
CN-110799490-B 3-arylpropionamide compound and method for producing 3-arylpropionate compound 住友化学株式会社 2023-05-02 CN disclosed
CN-114805050-A Preparation method of C-H bond carboxylation of aromatic hydrocarbon containing halogen 江苏百康德医药科技有限公司 2022-07-29 CN disclosed
US-11028056-B2 Method for producing 3-arylpropionamide compound and 3-arylpropionic acid ester compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-06-08 US disclosed
US-20200165209-A1 METHOD FOR PRODUCING 3-ARYLPROPIONAMIDE COMPOUND AND 3-ARYLPROPIONIC ACID ESTER COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2020-05-28 US disclosed
US-20070060569-A1 Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors NOVARTIS AG (CH) 2007-03-15 US disclosed
US-20070060569-A1 Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors NOVARTIS AG (CH) 2007-03-15 US disclosed
US-20070060754-A1 Alkoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2007-03-15 US disclosed
US-20070060754-A1 Alkoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2007-03-15 US disclosed
EP-1187811-B1 INHIBITORS OF METALLOPROTEINASES ASTRAZENECA AB (SE) 2007-03-07 EP disclosed
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors DEAN ANTHONY W 2007-03-01 US disclosed
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors DEAN ANTHONY W 2007-03-01 US disclosed
WO-2004103998-A1 QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-12-02 WO disclosed
EP-1094810-A1 USE OF PRENYLTRANSFERASE INHIBITORS FOR PREPARING A MEDICINE FOR TREATING PATHOLOGIES RESULTING FROM HETEROTRIMERIC G PROTEIN MEMBRANE FIXATION SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2001-05-02 EP disclosed
WO-2000002558-A1 USE OF PRENYLTRANSFERASE INHIBITORS FOR PREPARING A MEDICINE FOR TREATING PATHOLOGIES RESULTING FROM HETEROTRIMERIC G PROTEIN MEMBRANE FIXATION SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2000-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339878-A1 SLC26A3 INHIBITORS AND USE THEREOF SLC26A3, SLC10A2, SLC10A6 PGR 4458/4885MEN1 4700/4885ALDH1A1 2345/4885
US-20070060754-A1 Alkoxy substituted imidazoquinolines IL2, IFNG, IRF3 PGR 3227/4885MEN1 3720/4885ALDH1A1 918/4885
US-20070060569-A1 Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors MMP9, MMP1, MMP13 PGR 1955/4885MEN1 3101/4885ALDH1A1 207/4885
US-20200165209-A1 METHOD FOR PRODUCING 3-ARYLPROPIONAMIDE COMPOUND AND 3-ARYLPROPIONIC ACID ESTER COMPOUND AADAC, DDT, NAT1 PGR 2491/4885MEN1 3973/4885ALDH1A1 116/4885
US-20240092780-A1 ADDUCTS AND DIMER COMPOUNDS SYNTHESIZED USING GK METHOD DRD2, HNMT, DRD1 PGR 4362/4885MEN1 2440/4885ALDH1A1 1683/4885
US-11028056-B2 Method for producing 3-arylpropionamide compound and 3-arylpropionic acid ester compound AADAC, DDT, NAT1 PGR 2491/4885MEN1 3973/4885ALDH1A1 116/4885
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors PDE3B, PDE4B, PDE4A PGR 3285/4885MEN1 2927/4885ALDH1A1 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.